Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA VI: A Machine To Speed R&D Time, Cut Costs

The biopharmaceutical industry is hoping the terms set under the negotiations with the FDA for the sixth round of the Prescription Drug User Fee Act will help reduce the time and money spent on developing medicines, allowing companies to get their products into the commercial setting quicker and maximize those therapies' potential.

Commercial Companies Research & Development

China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns

The lack of a comprehensive regulatory pathway has not hindered Chinese researchers from forging ahead with the world's first human clinical study using CRISPR-Cas9 gene editing technology, which will be used to treat advanced lung cancer.

Research & Development Asia Pacific China

ABPI Unveils UK's Disclosure Site For Payments to Health Professionals

Disclosure UK, a new database requiring pharma companies to declare payments made to healthcare professionals, will record any payments made by companies to UK healthcare professionals for attending continuing professional development events, associated travel and hospitality costs, and any payments for work as advisers or consultants to companies.

Europe Legal Issues Market Intelligence

Korean Authorities Mull New Steps, Probe Over Olmutinib Events

Additional safety measures including a possible sales suspension are to be discussed by a review committee in South Korea on Oct. 4 that will help decide the fate of Hanmi’s EGFR inhibitor olmutinib. Financial authorities in the country are also launching a probe into the timing of the disclosure of several cases of serious adverse events with the drug.

Safety South Korea Policy & Regulation

French Trial Tragedy: Experts Recommend Tighter Phase I Rules

The French committee investigating the data behind the Phase I study of Bial's FAAH inhibitor BIA 10-2474, which resulted in the death of one volunteer and the hospitalization of five others in January 2016, has made a number of recommendations for tightening up the regulations on first-in-human studies.

Switzerland Clinical Trials